Lido Advisors
LGND icon

Lido Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Lido Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$550K Buy
2,757
+525
+24% +$104K ﹤0.01% 1249
2025
Q4 		$401K Buy
2,232
+31
+1% +$5.96K ﹤0.01% 1400
2025
Q3 		$390K Buy
2,201
+42
+2% +$6.24K ﹤0.01% 1346
2025
Q2 		$245K Buy
+2,159
New +$231K ﹤0.01% 1424

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Lido Advisors's LGND Position: Q1 2026 in Review

Lido Advisors increased its Ligand Pharmaceuticals (LGND) stake by 24% in Q1 2026, buying an estimated $104K and bringing the position to 2,757 shares worth $550K. The position accounts for ﹤0.01% of the portfolio, ranked #1249.

Lido Advisors first reported a position in LGND in Q2 2025 and has held it in 4 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Lido Advisors held 2,757 shares of Ligand Pharmaceuticals worth $550K as of Q1 2026.
  • Lido Advisors bought 525 Ligand Pharmaceuticals shares in Q1 2026, an estimated $104K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1249 holding.
  • Lido Advisors first reported a position in Ligand Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.